2.225
C 4 Therapeutics Inc stock is traded at $2.225, with a volume of 95,597.
It is down -0.48% in the last 24 hours and down -15.82% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.25
Open:
$2.25
24h Volume:
95,597
Relative Volume:
0.05
Market Cap:
$159.42M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.8333
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-1.79%
1M Performance:
-15.82%
6M Performance:
+80.58%
1Y Performance:
-58.99%
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CCCC
C 4 Therapeutics Inc
|
2.24 | 160.13M | 20.76M | -132.49M | -108.55M | -2.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
459.29 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
795.94 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-17-25 | Initiated | Barclays | Overweight |
Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
Sep-04-25 | Initiated | Guggenheim | Buy |
Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-18-24 | Initiated | Stephens | Equal-Weight |
Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-13-23 | Upgrade | Stifel | Hold → Buy |
Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Apr-28-22 | Initiated | Credit Suisse | Underperform |
Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
Mar-10-22 | Initiated | JP Morgan | Overweight |
Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
Nov-23-21 | Initiated | BofA Securities | Buy |
Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
Sep-30-21 | Initiated | Stifel | Hold |
Jun-04-21 | Initiated | H.C. Wainwright | Buy |
Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
Oct-28-20 | Initiated | UBS | Buy |
Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
How C4 Therapeutics Inc. stock reacts to oil prices2025 Volatility Report & Risk Managed Investment Signals - newser.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Promising Phase 1 Trial Results - MSN
C4 Therapeutics (NASDAQ:CCCC) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
C4 Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Low Risk Trading Ideas - earlytimes.in
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is C4 Therapeutics Inc. trending in predictive chart modelsWeekly Risk Report & High Yield Equity Trading Tips - newser.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Will C4 Therapeutics Inc. bounce back from current supportBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What analysts say about C4 Therapeutics Inc stockCup and Handle Formations & Capital Allocation Recommendations - earlytimes.in
Is Onix Solar Energy Limited Undervalued or Overvalued Fair Value ExplainedHigh Frequency Trading Trends & Small Entry Investment Ideas - earlytimes.in
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Announces Clinical Trial Collaboration and - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biotech Firm Protara Therapeutics Issues $4.41 Stock Options and RSUs in Key Employee Grant - Stock Titan
C4 Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - MarketScreener
C4 Therapeutics Partners with Pfizer for Phase 1b Clinical Trial of Cemsidomide in Combination with Elranatamab for Multiple Myeloma Treatment - Quiver Quantitative
Breakthrough Multiple Myeloma Treatment: C4 Therapeutics and Pfizer Join Forces for Novel Drug Combination Trial - Stock Titan
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Analyzing C4 Therapeutics Inc. with risk reward ratio chartsRate Cut & High Conviction Buy Zone Picks - newser.com
Has C4 Therapeutics Inc. formed a bullish divergenceJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Risk adjusted return profile for C4 Therapeutics Inc. analyzedJuly 2025 Technicals & Real-Time Volume Triggers - newser.com
Will C4 Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
How to monitor C4 Therapeutics Inc. with trend dashboardsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Will C4 Therapeutics Inc. benefit from macro trendsWeekly Stock Recap & High Accuracy Buy Signal Tips - newser.com
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
C 4 Therapeutics Inc Stock (CCCC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):